OXYGENTAPHPharmaceuticals
Oxygenta Pharmaceutical Ltd — Profit & Loss Statement
₹48.38
-3.44%
Oxygenta Pharmaceutical Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.09 Cr | 0.01 Cr | -0.22 Cr | 0.16 Cr | — |
| Tax Rate For Calcs | 0.28 | 0.30 | 0.30 | 0.30 | — |
| Normalized EBITDA | -6.80 Cr | -8.59 Cr | -7.11 Cr | 1.47 Cr | — |
| Total Unusual Items | -0.32 Cr | 0.04 Cr | -0.73 Cr | 0.55 Cr | — |
| Total Unusual Items Excluding Goodwill | -0.32 Cr | 0.04 Cr | -0.73 Cr | 0.55 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -10.30 Cr | -3.48 Cr | -11.57 Cr | -0.61 Cr | — |
| Reconciled Depreciation | 3.61 Cr | 2.66 Cr | 2.05 Cr | 1.59 Cr | — |
| Reconciled Cost Of Revenue | 107.63 Cr | 40.97 Cr | 30.58 Cr | 56.57 Cr | — |
| EBITDA | -7.12 Cr | -8.55 Cr | -7.85 Cr | 2.02 Cr | — |
| EBIT | -10.74 Cr | -11.21 Cr | -9.90 Cr | 0.43 Cr | — |
| Net Interest Income | -3.61 Cr | -2.66 Cr | -1.48 Cr | -0.92 Cr | — |
| Interest Expense | 3.61 Cr | 2.66 Cr | 1.47 Cr | 0.91 Cr | — |
| Normalized Income | -10.07 Cr | -3.51 Cr | -11.06 Cr | -0.99 Cr | — |
| Net Income From Continuing And Discontinued Operation | -10.30 Cr | -3.48 Cr | -11.57 Cr | -0.61 Cr | — |
| Total Expenses | 121.02 Cr | 50.93 Cr | 40.14 Cr | 60.64 Cr | — |
| Diluted NI Availto Com Stockholders | -10.30 Cr | -3.48 Cr | -11.57 Cr | -0.61 Cr | — |
| Net Income Common Stockholders | -10.30 Cr | -3.48 Cr | -11.57 Cr | -0.61 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -10.30 Cr | -3.48 Cr | -11.57 Cr | -0.61 Cr | — |
| Net Income Including Noncontrolling Interests | -10.30 Cr | -3.48 Cr | -11.57 Cr | -0.61 Cr | — |
| Net Income Continuous Operations | -10.30 Cr | -3.48 Cr | -11.57 Cr | -0.61 Cr | — |
| Tax Provision | -4.05 Cr | -10.39 Cr | 0.20 Cr | 0.12 Cr | — |
| Pretax Income | -14.35 Cr | -13.87 Cr | -11.37 Cr | -0.49 Cr | — |
| Other Non Operating Income Expenses | 1.31 Cr | 0.04 Cr | 0.01 Cr | 600.00 | — |
| Special Income Charges | -0.32 Cr | 0.04 Cr | -0.73 Cr | 0.55 Cr | — |
| Net Non Operating Interest Income Expense | -3.61 Cr | -2.66 Cr | -1.48 Cr | -0.92 Cr | — |
| Interest Expense Non Operating | 3.61 Cr | 2.66 Cr | 1.47 Cr | 0.91 Cr | — |
| Operating Income | -11.73 Cr | -11.29 Cr | -9.15 Cr | -0.12 Cr | — |
| Operating Expense | 13.39 Cr | 9.97 Cr | 9.56 Cr | 4.07 Cr | — |
| Other Operating Expenses | 4.71 Cr | 2.38 Cr | 0.79 Cr | 0.18 Cr | — |
| Depreciation And Amortization In Income Statement | 1.78 Cr | 1.59 Cr | 2.05 Cr | 1.59 Cr | — |
| Depreciation Income Statement | 1.78 Cr | 1.59 Cr | 2.05 Cr | 1.59 Cr | — |
| Gross Profit | 1.67 Cr | -1.32 Cr | 0.41 Cr | 3.96 Cr | — |
| Cost Of Revenue | 107.63 Cr | 40.97 Cr | 30.58 Cr | 56.57 Cr | — |
| Total Revenue | 109.30 Cr | 39.64 Cr | 30.99 Cr | 60.52 Cr | — |
| Operating Revenue | 109.30 Cr | 39.64 Cr | 30.99 Cr | 60.52 Cr | — |
| Interest Income | — | 0.02 Cr | 50000.00 | 44899.00 | 0.02 Cr |
| Rent Expense Supplemental | — | 0.18 Cr | 0.17 Cr | 0.08 Cr | 0.07 Cr |
| Diluted Average Shares | — | 3.19 Cr | 1.42 Cr | 1.27 Cr | 1.27 Cr |
| Basic Average Shares | — | 3.19 Cr | 1.42 Cr | 1.27 Cr | 1.02 Cr |
| Diluted EPS | — | -1.09 | -8.15 | -0.48 | 2.87 |
| Basic EPS | — | -1.09 | -8.15 | -0.48 | 2.87 |
| Net Income Discontinuous Operations | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Special Charges | — | -0.04 Cr | 0.73 Cr | -0.55 Cr | -2.19 Cr |
| Total Other Finance Cost | — | 0.01 Cr | 0.01 Cr | 0.01 Cr | 75376.00 |
| Interest Income Non Operating | — | 0.02 Cr | 50000.00 | 44899.00 | 0.02 Cr |
| Selling General And Administration | — | 2.14 Cr | 0.68 Cr | 1.51 Cr | 1.33 Cr |
| General And Administrative Expense | — | 2.14 Cr | 0.68 Cr | 1.51 Cr | 1.33 Cr |
| Rent And Landing Fees | — | 0.18 Cr | 0.17 Cr | 0.08 Cr | 0.07 Cr |
| Net Income Extraordinary | — | — | 0.00 | — | — |
| Amortization | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Oxygenta Pharmaceutical Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.